TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

PHASE3TerminatedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2014

Conditions
Diabetes
Interventions
DRUG

Placebo

TAK-875 placebo-matching tablets

DRUG

TAK-875

TAK-875 tablets

DRUG

TAK-875

TAK-875 tablets

Trial Locations (86)

60616

Apex Medical Research, MI, Inc, Chicago

Unknown

Birmingham

Dothan

Muscle Shoals

Phoenix

Anaheim

El Cajon

Long Beach

Modesto

North Hollywood

Norwalk

Pismo Beach

San Diego

Vista

West Hills

Boca Raton

Boynton Beach

Bradenton

Clearwater

Cocoa

Doral

Miami

North Miami

Pembroke Pines

Port Orange

Tampa

West Palm Beach

Atlanta

Savannah

Woodstock

Boise

Meridian

Chicago

Avon

Greenfield

Muncie

Council Bluffs

Topeka

Owensboro

Oxon Hill

Fall River

St Louis

Washington

Omaha

Nashua

Elizabeth

Haddon Heights

Albany

Rosedale

Calabash

Charlotte

Greensboro

Morganton

Winston-Salem

Dayton

Maumee

Norman

Oklahoma City

Feasterville

Harleysville

Levittown

Uniontown

Fort Mill

Greer

Spartanburg

Crossville

Knoxville

Carrollton

Dallas

Fort Worth

Houston

Irving

Katy

Lewisville

McKinney

New Braunfels

Plano

San Antonio

Tomball

Salt Lake City

Burke

Manassas

Ciudad Autonoma Buenos Aires

Salta

Rosario

Lima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT01829464 - TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes | Biotech Hunter | Biotech Hunter